Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $69
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has maintained an Outperform rating on LeMaitre Vascular (NASDAQ:LMAT) and increased the price target from $66 to $69.
February 28, 2024 | 4:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barrington Research has maintained an Outperform rating on LeMaitre Vascular and raised the price target from $66 to $69.
The upgrade in the price target by a reputable analyst firm like Barrington Research typically signals a positive outlook on the company's future performance, potentially leading to increased investor confidence and a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100